Sphingolipidoses and Retinal Involvement: A Comprehensive Review
Source abstract
Abstract
Sphingolipidoses are a class of inherited lysosomal storage diseases, characterized by enzymatic deficiencies that impair sphingolipid degradation. This enzymatic malfunction results in the pathological accumulation of sphingolipids within lysosomes, leading to tissue damage across multiple organ systems. Among the various organs involved, the eye and particularly the retina, can be affected and this will be the primary focus of this study. This article will explore the various subtypes of sphingolipidoses, detailing their associated retinal abnormalities, with an emphasis on multimodal imaging findings and clinical recognition of these rare disorders.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Lysosomal Storage Disorders Research · Cellular transport and secretion · Sphingolipid Metabolism and Signaling
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Ophthalmology Unit, Neurosciences, Mental Health, and Sense Organs (NESMOS) Department, Faculty of Medicine and Psychology, University of Rome Sapienza, 00189 Rome, Italy
Ophthalmology Unit, Sant’Andrea Hospital, Via di Grottarossa 1035/1039, 00189 Rome, Italy
References (100+)
Show source-provided references
1. Shaimardanova, A.A., Solovyeva, V.V., Issa, S.S., and Rizvanov, A.A. (2023). Gene Therapy of Sphingolipid Metabolic Disorders. Int. J. Mol. Sci., 24.10.3390/ijms24043627 ↗
2. Sphingolipid Lysosomal Storage Diseases: From Bench to Bedside10.1186/s12944-021-01466-0 ↗
3. Beyond the Cherry-Red Spot: Ocular Manifestations of Sphingolipid-Mediated Neurodegenerative and Inflammatory Disorders10.1016/j.survophthal.2013.02.005 ↗
4. Novel HEXA Variants in Korean Children with Tay-Sachs Disease with Regression of Neurodevelopment from Infancy10.1002/mgg3.1677 ↗
5. The Appearance of Newly Identified Intraocular Lesions in Gaucher Disease Type 3 despite Long-Term Glucocerebrosidase Replacement Therapy10.3109/03009734.2016.1158756 ↗
6. Tripathy, K., and Patel, B.C. (2024). Cherry Red Spot. StatPearls, StatPearls Publishing.
7. Cujbă, L., Banc, A., Stan, C., Drugan, T., and Nicula, C. (2024). Macular OCT’s Proficiency in Identifying Retrochiasmal Visual Pathway Lesions in Multiple Sclerosis—A Pilot Study. Diagnostics, 14.10.3390/diagnostics14121221 ↗
8. Seeing beyond Gaucher Disease: Early Detection and Treatment of Ocular Complications10.4103/IJO.IJO_996_23 ↗
9. Shiga, Y., Nishida, T., Jeoung, J.W., Di Polo, A., and Fortune, B. (2023). Optical Coherence Tomography and Optical Coherence Tomography Angiography: Essential Tools for Detecting Glaucoma and Disease Progression. Front. Ophthalmol., 3.10.3389/fopht.2023.1217125 ↗
10. Optical Coherence Tomography Angiography Analysis of Fabry Disease10.1007/s10792-020-01486-2 ↗
11. Investigation of Ocular Involvement in Patients with Fabry Disease10.1080/07853890.2023.2226909 ↗
12. Retinal Vessel Tortuosity as a Prognostic Marker for Disease Severity in Fabry Disease10.1186/s13023-021-02080-0 ↗
13. Neurophysiological Investigations in GM1 and GM2 Gangliosidoses10.1055/s-2008-1052386 ↗
14. Kulyabin, M., Zhdanov, A., Dolganov, A., Ronkin, M., Borisov, V., and Maier, A. (2023). Enhancing Electroretinogram Classification with Multi-Wavelet Analysis and Visual Transformer. Sensors, 23.10.3390/s23218727 ↗
15. Functional Retinal Changes in Gaucher Disease10.1007/s10633-008-9142-9 ↗
16. Diagnostic and Predictive Methods for a Niemann-Pick Disease Type B Patient with Ocular Involvement10.1007/s10545-010-9153-z ↗
17. Visually Evoked Potentials10.1016/B978-0-444-64032-1.00034-5 ↗
18. Bettinger, C.M., Dulz, S., Atiskova, Y., Guerreiro, H., Schön, G., Guder, P., Maier, S.L., Denecke, J., and Bley, A.E. (2024). Overview of Neuro-Ophthalmic Findings in Leukodystrophies. J. Clin. Med., 13.10.3390/jcm13175114 ↗
19. Neurochemical, Morphological, and Neurophysiological Abnormalities in Retinas of Sandhoff and GM1 Gangliosidosis Mice10.1111/j.1471-4159.2007.04525.x ↗
20. Ultra-Wide-Field Imaging in Diabetic Retinopathy10.1016/j.visres.2017.02.009 ↗
21. Pathologic Myopia: Advances in Imaging and the Potential Role of Artificial Intelligence10.1136/bjophthalmol-2021-320926 ↗
22. Optical Coherence Tomography Angiography: A Comprehensive Review of Current Methods and Clinical Applications10.1016/j.preteyeres.2017.07.002 ↗
23. Parkinson’s Disease: What Can Retinal Imaging Tell Us?10.31083/j.jin2301023 ↗
24. Retinal Imaging in Alzheimer’s and Neurodegenerative Diseases10.1002/alz.12179 ↗
25. Neurocognitive Assessment and Retinal Thickness Alterations in Alzheimer Disease: Is There a Correlation?10.1097/WNO.0000000000000831 ↗
26. Past, Present and Future Role of Retinal Imaging in Neurodegenerative Disease10.1016/j.preteyeres.2020.100938 ↗
27. Sandhoff’s Disease (GM2 Gangliosidosis Type 2). Histopathology and Ultrastructure of the Eye10.1001/archopht.1980.01020031079014 ↗
28. Weill, Y., Zimran, A., Zadok, D., Wasser, L.M., Revel-Vilk, S., Hanhart, J., Dinur, T., Arkadir, D., and Becker-Cohen, M. (2020). Macular Ganglion Cell Complex and Peripapillary Retinal Nerve Fiber Layer Thinning in Patients with Type-1 Gaucher Disease. Int. J. Mol. Sci., 21.10.3390/ijms21197027 ↗
29. Retinal Thinning in Gaucher Disease Patients and Carriers: Results of a Pilot Study10.1016/j.ymgme.2013.04.001 ↗
30. Fabry Disease: A Review of Ophthalmic and Systemic Manifestations10.1097/OPX.0b013e31827ec7eb ↗
31. Optical Coherence Tomography Angiography10.1016/j.preteyeres.2017.11.003 ↗
32. Sialidosis Type I: Ophthalmological Findings10.1136/bcr-2014-205871 ↗
33. Optical Coherence Tomography Findings in a Patient with Type 1 Sialidosis
34. Clinical, Imaging, Genetic, and Disease Course Characteristics in Patients with GM2 Gangliosidosis: Beyond Age of Onset10.1212/WNL.0000000000207898 ↗
35. Acid Ceramidase Deficiency: Farber Disease and SMA-PME10.1186/s13023-018-0845-z ↗
36. Khan, A., and Sergi, C. (2018). Sialidosis: A Review of Morphology and Molecular Biology of a Rare Pediatric Disorder. Diagnostics, 8.10.3390/diagnostics8020029 ↗
37. Multimodal Imaging Including Optical Coherence Tomography Angiography in Patients with Type B Niemann-Pick Disease10.1007/s10792-019-01102-y ↗
38. Investigation of OCTA Biomarkers in Fabry Disease: A Long Term Follow-Up of Macular Vessel Area Density and Foveal Avascular Zone Metrics10.1007/s40123-023-00776-z ↗
39. Fundus Autofluorescence10.1007/978-3-319-95046-4_4 ↗
40. Clinical Application of Ultra-Widefield Fundus Autofluorescence10.1007/s10792-020-01609-9 ↗
41. Fluorescein Angiography10.1007/978-3-319-95046-4_2 ↗
42. Ophthalmic Fluorescein Angiography
43. Clinical Application of Adaptive Optics Imaging in Diagnosis, Management, and Monitoring of Ophthalmological Diseases: A Narrative Review10.12659/MSM.941926 ↗
44. Adaptive Optics: Principles and Applications in Ophthalmology10.1038/s41433-020-01286-z ↗
45. In Vivo Observation of Retinal Vascular Deposits Using Adaptive Optics Imaging in Fabry Disease10.1097/IAE.0000000000002648 ↗
46. Adaptive Optics Technology for High-Resolution Retinal Imaging10.3390/s130100334 ↗
47. Blood Vessel Tail Artifacts Suppression in Optical Coherence Tomography Angiography10.1117/1.NPh.9.2.021906 ↗
48. Electroretinograms10.1016/B978-0-444-64032-1.00032-1 ↗
49. Bhatt, Y., Hunt, D.M., and Carvalho, L.S. (2023). The Origins of the Full-Field Flash Electroretinogram b-Wave. Front. Mol. Neurosci., 16.10.3389/fnmol.2023.1153934 ↗
50. The Multifocal Electroretinogram10.1097/00041327-200309000-00008 ↗
51. Baiano, C., and Zeppieri, M. (2025). Visual Evoked Potential. StatPearls, StatPearls Publishing.
52. International Society for Clinical Electrophysiology of Vision, Odom, J.V., Bach, M., Brigell, M., Holder, G.E., McCulloch, D.L., Mizota, A., and Tormene, A.P. (2016). ISCEV Standard for Clinical Visual Evoked Potentials: (2016 Update). Doc. Ophthalmol., 133, 1–9.10.1007/s10633-016-9553-y ↗
53. Chromatic Visual Evoked Potentials: A Review of Physiology, Methods and Clinical Applications10.1016/j.preteyeres.2024.101272 ↗
54. (2025, January 25). A Case Refort of Sandhoff Disease—PubMed, Available online: https://pubmed.ncbi.nlm.nih.gov/15929490/.
55. Ocular Manifestations in Tay-Sachs’ and Niemann-Pick’s Diseases. (A Clinical, Pathological, Histochemical and Biochemical Investigation)10.1111/j.1755-3768.1965.tb05452.x ↗
56. History, Genetic, and Recent Advances on Krabbe Disease10.1016/j.gene.2014.09.046 ↗
57. Ultrastructural Study of the Retina in Late Infantile Metachromatic Leukodystrophy10.1159/000267154 ↗
58. Clinical and Ultrastructural Ocular Histopathologic Studies of Adult-Onset Metachromatic Leukodystrophy10.1016/0002-9394(76)90497-9 ↗
59. The Niemann-Pick Type Diseases—A Synopsis of Inborn Errors in Sphingolipid and Cholesterol Metabolism10.1016/j.plipres.2023.101225 ↗
60. Niemann-Pick Diseases10.1016/B978-0-444-59565-2.00041-1 ↗
61. Niemann-Pick Disease: An Approach for Diagnosis in Adulthood
62. Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (1993). Acid Sphingomyelinase Deficiency. GeneReviews®, University of Washington, Seattle.
63. Macula Halo Syndrome10.1007/s10792-018-0939-6 ↗
64. Servín Muñoz, I.V., Ortuño-Sahagún, D., Griñán-Ferré, C., Pallàs, M., and González-Castillo, C. (2024). Alterations in Proteostasis Mechanisms in Niemann-Pick Type C Disease. Int. J. Mol. Sci., 25.10.3390/ijms25073806 ↗
65. High Incidence of Unrecognized Visceral/Neurological Late-Onset Niemann-Pick Disease, Type C1, Predicted by Analysis of Massively Parallel Sequencing Data Sets10.1038/gim.2015.25 ↗
66. The Expanding Boundaries of Sphingolipid Lysosomal Storage Diseases; Insights from Niemann-Pick Disease Type C10.1042/BST20220711 ↗
67. Bilateral Macular Halo and Full-Thickness Macular Hole Repair in Niemann-Pick Disease Type B
68. Inner Macular Hyperreflectivity Demonstrated by Optical Coherence Tomography in Niemann-Pick Disease10.1001/jamaophthalmol.2013.2374 ↗
69. Ocular manifestation of an adult Niemann-Pick disease type B10.1556/650.2023.32927 ↗
70. Microperimetry in Three Inherited Retinal Disorders10.1080/08820538.2019.1622025 ↗
71. Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., and Brassier, A. (2017). A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int. J. Mol. Sci., 18.10.3390/ijms18020441 ↗
72. An Overview on Bone Manifestations in Gaucher Disease10.1007/s10354-010-0841-y ↗
73. The French Gaucher’s Disease Registry: Clinical Characteristics, Complications and Treatment of 562 Patients10.1186/1750-1172-7-77 ↗
74. Gaucher Disease: New Expanded Classification Emphasizing Neurological Features
75. Gaucher Disease: Complexity in a “Simple” Disorder10.1016/j.ymgme.2004.08.015 ↗
76. Eye Movement Biomarkers Allow for the Definition of Phenotypes in Gaucher Disease10.1186/s13023-020-01637-9 ↗
77. Ophthalmological Findings in Gaucher Disease10.1016/j.ymgme.2019.02.002 ↗
78. Prakash, G., and Iwata, T. (2017). Ocular Implications of Gaucher Disease. Advances in Vision Research, Volume I: Genetic Eye Research in Asia and the Pacific, Springer.
79. Type 2 Gaucher Disease: Phenotypic Variation and Genotypic Heterogeneity10.1016/j.bcmd.2010.08.012 ↗
80. Vitreous Opacities and Retinal Vascular Abnormalities in Gaucher Disease10.1001/archopht.122.9.1395 ↗
81. Evaluation of Sphingolipids in Vitreous Bodies from a Patient with Gaucher Disease, Using Delayed Extraction Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry10.1016/j.jchromb.2004.02.027 ↗
82. A Comprehensive Monocentric Ophthalmic Study with Gaucher Disease Type 3 Patients: Vitreoretinal Lesions, Retinal Atrophy and Characterization of Abnormal Saccades10.1186/s13023-019-1244-9 ↗
83. White Vitreous Opacities in Five Patients with Gaucher Disease Type10.1002/ajmg.a.61479 ↗
84. Photo Essay: Retinal Changes in Type 3 Gaucher Disease10.1080/01658107.2017.1420084 ↗
85. Phenotype, Diagnosis, and Treatment of Gaucher’s Disease10.1016/S0140-6736(08)61522-6 ↗
86. Isolated Horizontal Supranuclear Gaze Palsy as a Marker of Severe Systemic Involvement in Gaucher’s Disease10.1212/WNL.43.10.1993 ↗
87. Gaucher Disease Type 3c: Expanding the Clinical Spectrum of an Ultra-Rare Disease
88. Gaucher Disease Type 3c: New Patients with Unique Presentations and Review of the Literature10.1016/j.ymgme.2019.05.011 ↗
89. Preretinal White Dots in Adult-Type Gaucher Disease10.1097/00006982-199919060-00019 ↗
90. Preretinal and Posterior Vitreous Deposits in Gaucher Disease10.1001/jamaophthalmol.2013.7817 ↗
91. Vitreous Hemorrhage in Type 3 Gaucher Disease: An Angiographic and Pathologic Analysis10.1097/ICB.0000000000001064 ↗
92. Analysis of the Pre-Retinal Opacities in Gaucher Disease Using Spectral Domain Optical Coherent Tomography10.3109/13816810.2012.716489 ↗
93. A Case of Traction Retinal Detachment in a Patient with Gaucher Disease10.1080/13816810.2016.1193878 ↗
94. GM1 Gangliosidosis and Morquio B Disease: An Update on Genetic Alterations and Clinical Findings10.1016/j.bbadis.2011.03.018 ↗
95. GM1 Gangliosidosis: Mechanisms and Management10.2147/TACG.S206076 ↗
96. GM1 Gangliosidosis: Review of Clinical, Molecular, and Therapeutic Aspects10.1016/j.ymgme.2008.04.012 ↗
97. Type 3 GM1 Gangliosidosis: Clinical and Neuroradiological Findings in an 11-Year-Old Girl10.1007/BF00878872 ↗
98. Dystonia and Parkinsonism in GM1 Type 3 Gangliosidosis10.1002/mds.20593 ↗
99. GM1-Gangliosidosis. Ocular and Pathological Manifestations10.1001/archopht.1971.00990050179011 ↗
100. Cherry-Red Spot, Optic Atrophy and Corneal Cloudings in a Patient Suffering from GM1 Gangliosidosis Type I